← Back to headlines
Eli Lilly Expands AI Drug Development with Multibillion-Dollar Insilico Deal
Global pharmaceutical company Eli Lilly has finalized a $2.75 billion deal with Hong Kong-based Insilico, including $115 million upfront, to bring AI-discovered drugs to the global market, further expanding its push into artificial intelligence for drug development.
29 Mar, 11:00 — 29 Mar, 13:47
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (51/100)3 sources25/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
cnbc
Center1
Center (1)
FT
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US2UK1
Sources
Showing 3 of 3 sources
FTVery High3h ago
Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech
Global pharmaceutical companies are aggressively searching for new medicines in China
Read full article →cnbcMostly Factual37m ago
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the global market.
Read full article →seeking-alphaMixed27m ago
Eli Lilly expands AI drug push with multibillion-dollar Insilico deal
Read full article →Coverage Timeline
First report: FT · 29 Mar, 11:00|Full coverage: 3 · 3h|Window: 3h
Left-leaningCenterRight-leaning
